Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats by Price, PA et al.
Discovery of a High Molecular Weight Complex of Calcium,
Phosphate, Fetuin, and Matrix -Carboxyglutamic Acid
Protein in the Serum of Etidronate-treated Rats*
Received for publication, July 9, 2001, and in revised form, November 19, 2001
Published, JBC Papers in Press, November 27, 2001, DOI 10.1074/jbc.M106366200
Paul A. Price‡, Gethin R. Thomas, Aaron W. Pardini, William F. Figueira, Jeffrey M. Caputo,
and Matthew K. Williamson
From the Division of Biology, University of California, San Diego, La Jolla, California 92093-0368
In the present study we report the discovery of a novel
protein-mineral complex in the serum of rats treated
with doses of the bone-active bisphosphonate etidronate
that inhibit normal bone mineralization. The composi-
tion of this high molecular mass protein-mineral com-
plex consists of about 18% mineral, 80% fetuin, and 2%
matrix Gla protein (MGP) by weight, and the presence
of the complex in serum after an injection of 8 mg
etidronate/100 g of body weight elevates calcium by 1.8-
fold (to 4.3 mM), phosphate by 1.6-fold (to 5.6 mM), and
MGP by 25-fold (to 12 g/ml). The serum mineral com-
plex reaches maximal levels at 6 h after subcutaneous
injection of etidronate and is subsequently cleared from
serum by 24 h. This highly specific complex of fetuin,
MGP, and mineral prevents the growth, aggregation,
and precipitation of the mineral component, which in-
dicates that the previously reported calcification inhib-
itory activities of fetuin and MGP may be related to
their ability to form stable complexes with nascent min-
eral nuclei. Treatment with the vitamin K-antagonist
warfarin prevents the increase in serum MGP after
etidronate injection, which shows that the increase in
serum MGP is due to new synthesis and that the -car-
boxylation of MGP is necessary for its binding to the
serum mineral complex.
The initial objective of the present investigations was to
understand how matrix Gla protein (MGP)1 inhibits the abnor-
mal calcification of arteries and other soft tissues. Recent ge-
netic and biochemical studies have established MGP as the
first protein known to act as a calcification inhibitor in vivo. In
humans, defects in the MGP gene that predict a non-functional
MGP protein have been shown to be responsible for Keutel
syndrome (1), a rare inherited disease characterized by multi-
ple peripheral pulmonary artery stenoses, by abnormal calcifi-
cation of cartilages, including costal, nasal, auricle, tracheal,
and growth plate cartilage, and by nasal hypoplasia and
brachytelephalangia (2, 3). In mice, targeted deletion of the
MGP gene causes rapid calcification of the elastic lamellae of
the arterial media, which begins at birth and is sufficiently
extensive by 3–6 weeks of age that the arteries become rigid
tubes that fracture, causing death by exsanguination in most of
the affected mice by 6 weeks of age (4). MGP-deficient mice also
display abnormal calcification of growth plate and tracheal ring
cartilage. Finally, treatment of rats with the vitamin K antag-
onist warfarin at doses that inhibit the -carboxylation of MGP
causes rapid calcification of elastic lamellae of arteries and of
aortic heart valves and increased expression of MGP mRNA in
the calcifying artery (5, 6).
Matrix Gla protein is a 10-kDa secreted protein that was
originally discovered in demineralization extracts of bone but is
now known to be expressed by a wide variety of tissues and cell
types. The rat tissues with the highest levels of MGP mRNA
are cartilage, heart, kidney, and lung (7, 8), and cells known to
express MGP mRNA include osteoblasts, chondrocytes, vascu-
lar smooth muscle cells, pneumocytes, kidney cells, and fibro-
blasts (7–12). Although several noncalcified tissues do express
MGP mRNA at a higher level than bone, significant levels of
the protein itself have only been found in bone and calcified
cartilage (8, 13). This observation suggests that the protein
may accumulate at sites of calcification and that much of the
protein secreted by noncalcified tissues probably escapes to
plasma, where MGP is found at 0.3–1 g/ml depending on the
species. MGP contains five residues of the vitamin K-depend-
ent calcium binding amino acid, -carboxyglutamic acid (Gla)
(14, 15) and three residues of phosphoserine located at con-
served N-terminal sequence positions in MGP from shark, rat,
cow, and human tissues (16). Specific proteolytic cleavage at a
conserved dibasic site in the C-terminal region has also been
observed for MGP isolated from human, bovine, and shark
tissues (13, 17).
The original objective of the present study was to use the
geminal bisphosphonate etidronate (ethylhydroxybisphospho-
nate) to probe the function of MGP in bone metabolism. These
studies were prompted by the fact that etidronate and MGP
both bind strongly to bone mineral and by previous studies that
showed that etidronate competes with bone Gla protein (BGP;
osteocalcin), a related vitamin K-dependent protein, for bind-
ing to hydroxyapatite in vitro, and that etidronate injection
into a rat produced a transient 3-fold elevation in serum BGP
levels (18). We report here that etidronate produced a greater
than 25-fold elevation in serum levels of MGP within 6 h and
that this elevation is caused by the unexpected appearance of a
novel complex of calcium, phosphate, fetuin, and MGP in serum
after etidronate injection. The structure and properties of this
complex have direct relevance to an understanding of how
MGP normally inhibits calcification in vivo.
EXPERIMENTAL PROCEDURES
Materials—Simonsen albino male rats (Sprague-Dawley-derived)
were purchased from Simonsen labs (Gilroy, Ca). Etidronate was a gift
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from Proctor and Gamble (Cincinnati, OH). Sephacryl S-300 HR gel
filtration media was purchased from Amersham Biosciences, Inc. Ul-
trafree CL filtration devices were purchased from Millipore Corp. War-
farin was purchased from Sigma. Stock solutions of sodium warfarin
were prepared at 50 mg/ml in 0.15 M NaCl and stored in sterile foil-
wrapped containers at 4 °C. MGP was purified from rat bone as de-
scribed (17). Rabbit antibodies against rat fetuin were prepared as
described (19). All other reagents used were reagent grade or better.
Maintenance of Animals—Rats were fed rodent diet 5001 (Purina
Mills Inc., St. Louis, MO), a diet that is 0.67% phosphorus and 0.95%
calcium by weight. Etidronate was dissolved with 0.15 M NaCl, titrated
to pH 7.4 with dilute NaOH, and administered subcutaneously to 40-
day-old male rats. Control animals received injections of 0.15 M NaCl
only. In the initial time course experiment (Fig. 1), 5 40-day-old male
rats were injected with 8 mg of etidronate/100 g of body weight at t  0.
At the times indicated in Fig. 1, each rat was anesthetized with meto-
fane, and a 400-l sample of blood was withdrawn from the jugular
vein. Blood samples were allowed to clot for 15 min at room tempera-
ture, and serum was obtained after centrifugation in a clinical centri-
fuge and then frozen rapidly on dry ice and stored at 70 °C until later
analysis. The same procedure was followed for the second time course
experiment (Fig. 2), with the difference that the etidronate dose was
increased to 32 mg/100 g of body weight.
To determine the effect of warfarin on the generation of the serum
protein-mineral complex, 4 rats received subcutaneous injections of
15.4 mg of warfarin/100 g of body weight, and 4 rats received injections
of saline vehicle. Two hours later, all rats were injected with etidronate
at a dose of 8 mg/100 g (t  0), and 400 l of blood were removed from
each animal at the indicated times for biochemical analyses. Control
experiments were also carried out in which four animals received war-
farin but not etidronate and four animals were injected with saline
vehicle only. In neither control group could we detect a significant
change in serum levels of calcium, phosphate, or MGP at any time
point.
To examine the possible linkage between the generation of the serum
mineral complex and inhibition of bone mineralization, 12 100-g rats
were injected with 4 mg of etidronate at t 0 and were then divided into
2 groups of 6 rats each. 0.5-ml blood samples were obtained from the
group 1 rats at t  0, 2, 6, and 12 h, and the rats were exsanguinated
at t  24 h. The group 2 rats were injected with a second dose of
etidronate at t  24 h, and 0.5-ml blood samples were obtained at t 
24, 26, 30, and 36 h. These rats were exsanguinated at t  48 h. Serum
was obtained at each time point and stored at 20 °C until later
analysis. Tibias from the rats killed at 48 h as well as from age-matched
controls were removed, cleaned of adhering tissue, and fixed in 70%
ethanol. Tibia samples were embedded in plastic and cut into sections
of 500 m by Pathology Associates International (Frederick, MD). The
resulting sections were microradiographed using a Hewlett-Packard
model 4380N Faxitron x-ray machine. All animal experiments were
approved by the University of California at San Diego animal subjects
committee.
Biochemical Characterization of the Complex between Calcium, Phos-
phate, Fetuin, and MGP—The serum mineral complex was character-
ized by filtration using Ultrafree CL filtration devices with a 300-kDa
molecular mass cut-off membrane. In a typical experiment, blood was
obtained from 2 control rats and from 2 rats 6 h after a dose of 8 mg of
etidronate/100 g of body weight, and each blood sample was immedi-
ately placed into a 2.5-ml gold top Vacutainer tube (SST gel and clot
activator tube, Becton Dickinson). Thirty minutes later 1-ml aliquots of
the serum were removed, placed into the filtration device, and centri-
fuged for 80 min at 2500 g to force the sample through the membrane.
The filtrate and retentate were then analyzed to determine calcium,
phosphate, and volume. The typical filtrate volume recovered was 0.70
ml, and the typical retentate volume recovered was 0.26 ml.
The effect of centrifugation on the serum mineral complex was in-
vestigated in serum samples obtained 6 h after administration of eti-
dronate at doses of 8 mg/100 g and 32 mg/100 g of body weight. At the
lower dose, no significant amount of calcium, phosphate, or MGP was
sedimented after centrifugation for 30 min at 16,000  g. At the higher
dose, a well defined translucent pellet was obtained after centrifugation
for 30 min at 16,000 g. This pellet was dissolved in 1 ml of 50 mM HCl
and analyzed for calcium, phosphate, and MGP.
The serum mineral complex was characterized by gel filtration using
25-ml columns of Sephacryl S-300 HR that were prepared in disposable
plastic pipettes and were equilibrated with 20 mM HEPES, pH 7.4, 0.15
M NaCl, and 10 mM CaCl2 at room temperature. Serum was obtained
from rats 6 h after administration of etidronate at a dose of 8 mg/100 g,
and 1-ml aliquots were immediately applied to the Sephacryl column.
Fractions of 0.5 ml were then collected and analyzed to determine the
level of phosphate and MGP.
Analytical Methods—For determination of MGP and BGP, aliquots of
fractions and serum samples were diluted into diluent and assayed in
triplicate using radioimmunoassay procedures previously described
(12, 13). Calcium levels in serum and other samples were determined
colorimetrically using cresolphthalein complexone (Sigma), and phos-
phate levels in serum, effluent fractions, and other samples were de-
termined colorimetrically as described (20). For determination of ionic
calcium, freshly obtained blood samples were immediately placed into a
2.5-ml gold top Vacutainer tube to avoid out-gassing of CO2 and the
associated shift in pH. Clotted blood was centrifuged for 10 min in a
clinical centrifuge, and serum was analyzed for ionic calcium at the
University of California, San Diego Medical Center Chemistry Labora-
tory. Electrophoresis was carried out using 4–20% polyacrylamide gels
(Novex, Inc., San Diego, CA) run in Tris-glycine buffer containing SDS.
In the Western blot experiment shown in Fig. 4B, 100 l of etidronate
serum obtained as described in Table II was centrifuged at 16,000  g
for 30 min at room temperature. The supernatant was then removed,
and the pellet was dissolved with 100 l of SDS loading buffer contain-
ing 60 mM EDTA. Dilutions were made with the same SDS/EDTA
loading buffer so that the 20 l loaded onto the gel contained 0.1 l of
serum from a control rat, 0.1 l of serum from the etidronate-treated rat
before centrifugation, or 0.1 l of the supernatant or dissolved pellet
obtained after centrifugation. After electrophoresis on a 4–20% poly-
acrylamide gel, proteins were transferred to nitrocellulose, incubated
overnight with rabbit antibody against rat fetuin (1:500 dilution in
TBST), and detected using alkaline phosphatase-conjugated second
antibody (Sigma). Protein sequencing was carried out on bands trans-
ferred to polyvinylidene difluoride membranes using a Procise 494
Sequencer (ABI division, PE Biosystems, Foster City, CA).
RESULTS
Effect of High Etidronate Doses on Serum Levels of Phos-
phate, Total Calcium, Ionic Calcium, and Matrix Gla Protein—
The initial study was carried out to determine the effect of
etidronate on serum MGP levels using a subcutaneous dose
that, in a previous study, was found to elicit an elevation in
serum levels of BGP (18), a vitamin K-dependent bone protein
related in sequence to MGP. Serum was obtained from rats
at different times after the subcutaneous administration of
etidronate at a dose of 8 mg/100 g of body weight, and each
serum sample was then analyzed for levels of MGP and BGP by
radioimmunoassay. In agreement with the earlier study (18),
serum levels of BGP were elevated by a maximum of 3-fold, and
the peak serum BGP level was observed at 1 h (data not
shown). In marked contrast, serum MGP levels were increased
by 25-fold rather than 3-fold, and the peak level of MGP was
observed at 6 h rather than at 1 h.
Because MGP is known to inhibit the calcification of arteries
and other soft tissues (5, 6), we suspected that the dramatic
serum MGP response to etidronate could be associated with the
appearance of a calcium phosphate mineral complex in serum.
We accordingly carried out a second experiment in which we
measured serum levels of MGP, calcium, and phosphate at
different times after the administration of etidronate. As
shown in Fig. 1, serum calcium and phosphate levels increased
rapidly after subcutaneous injection of etidronate, and by 6 h
the levels of total calcium and phosphate were 76 and 59%
above control levels, respectively. Serum levels of MGP in-
creased more slowly than total serum calcium and phosphate
levels, with half of the maximal levels at 3 h for MGP compared
with 1 h for calcium and phosphate.
To determine whether the rise in total calcium after
etidronate administration is due to an increase in ionic calcium
or to an increase in a calcium complex, in a follow up experi-
ment 4 rats were exsanguinated at t  0, 1, 2, and 6 h after
injection of 8 mg of etidronate/100 g of body weight, and the
level of ionic and total calcium were measured in each serum
sample. Ionic calcium values were 1.46  0.03 mM at t  0 h,
1.47  0.04 mM at 1 h, 1.51  0.04 mM at 2 h, and 1.46  0.03
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mM at 6 h, whereas total calcium levels were 2.45  0.11 mM at
t 0 h, 3.45 0.34 mM at 1 h, 4.05 0.44 mM at 2 h, and 4.41
0.43 mM at 6 h. The failure of etidronate to cause a rise in ionic
calcium levels indicates that the increase observed in total
calcium levels must be due to the appearance of a non-ionic
form of calcium in serum. Because there is a parallel increase
in serum phosphate and total calcium levels after etidronate
injection (Fig. 1), it seemed likely that this non-ionic form of
serum calcium is a complex of calcium and phosphate.
As seen in Fig. 2, a 4-fold higher subcutaneous dose of
etidronate produced a greater elevation in serum total calcium,
phosphate, and MGP. The time course of the response to the
32-mg/100-g etidronate dose was similar to the response seen
with the 8 mg/100 g dose over the first 9 h, with a maximal level
in serum total calcium, phosphate, and MGP at 6–9 h after
treatment with 32 mg/100 g etidronate. Serum levels of total
calcium, phosphate, and MGP remained substantially elevated
at 24 h after the 32 mg/100 g dose of etidronate, however,
suggesting that the higher dose prolongs the serum response.
Despite the 4.5-fold increase in serum total calcium at 6 h after
treatment with 32 mg/100 g of etidronate, there was no in-
crease in the level of serum-ionized calcium at 6 h, which
further supports the conclusion that the increase in serum
calcium is due to the appearance of a calcium complex. A 2-fold
lower etidronate dose of 4 mg/100 g of body weight produced a
smaller increase in serum calcium, phosphate, and MGP at 6 h
than the 8 mg/100 g dose (data not shown). In contrast, the
amino bisphosphonate alendronate had no effect on serum
calcium, phosphate, and MGP levels measured at 1, 2, 6, 12,
and 24 h after administration of a 4 mg/100 g dose of the drug
(data not shown).
Filtration Evidence for a High Molecular Weight Complex of
Calcium, Phosphate, and MGP in the Serum of Etidronate-
treated Rats—To further characterize the calcium complex that
is responsible for the rise in total calcium but not ionic calcium
after etidronate injection, serum from etidronate-treated and
control rats was filtered through 300-kDa molecular mass cut
off membranes using an Ultrafree CL filtration device, and the
filtrate and retentate fractions were separately analyzed for
calcium, phosphate, and MGP. As can be seen in Table I, the
increase in total serum calcium, phosphate, and MGP levels
produced by the 8 mg/100 g dose of etidronate proved to be due
to an increase in the levels of calcium, phosphate, and MGP in
the high molecular mass retentate fraction, and the filtrate
levels of calcium and phosphate were the same for control and
etidronate-treated rats. This result indicates that the increases
in total calcium, phosphate, and MGP seen in the serum of rats
treated with etidronate is probably due to the appearance of a
high molecular mass serum complex of calcium, phosphate, and
MGP.
To determine the stability of the putative serum mineral
complex, another 1-ml aliquot of serum from the etidronate-
FIG. 1. Effect of an 8-mg/100-g etidronate dose on serum levels
of calcium, phosphate, and matrix Gla protein. Five forty-day-
old male Sprague-Dawley rats were given subcutaneous injections of
etidronate at a dose of 8 mg/100 g body weight at t  0. Blood was
removed from each animal at the indicated times and analyzed to
determine the levels of calcium, phosphate, and MGP (see “Experimen-
tal Procedures”). Each data point is the average of the individually
determined levels in the 5 experimental animals, and the error bars
denote the S.D. Panel A, serum calcium, mM; panel B, serum phosphate,
mM; panel C, serum MGP, g/ml.
FIG. 2. Effect of a 32-mg/100-g etidronate dose on serum levels
of calcium, phosphate, and matrix Gla protein. Three forty-day-
old male Sprague-Dawley rats were given subcutaneous injections of
etidronate at a dose of 32 mg/100 g body weight at t  0. Blood was
removed from each animal at the indicated times and analyzed to
determine the levels of calcium, phosphate, and MGP (see “Experimen-
tal Procedures”). Each data point is the average of the individually
determined levels in the three experimental animals. f, serum calcium,
mM; E, serum phosphate, mM; ‚, serum MGP, g/ml.
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treated rats (see Table I legend) was placed into a sealed tube,
incubated at room temperature for 1 day, and then filtered
through a 300-kDa molecular mass cut off membrane using the
method described in Table I. The levels of calcium, phosphate,
and MGP in the resulting retentate and filtrate fractions were
comparable with the values found for serum filtered immedi-
ately after serum was obtained (shown in Table I), with reten-
tate calcium levels of 2.83 mol, phosphate levels of 2.02 mol,
and MGP levels of 12,127 ng, and with filtrate calcium levels of
1.21 mol, phosphate levels of 2.79 mol, and MGP levels of
320 ng. This result shows that the putative calcium phosphate
mineral phase found in the serum of an etidronate-treated rat
does not grow at the expense of free calcium and phosphate
levels in serum. In another stability test, a 1-ml aliquot of
serum from the etidronate-treated rat was frozen on dry ice
and thawed 5 times and then subjected to filtration. Retentate
and filtrate levels of calcium, phosphate, and MGP levels were
again comparable with the values shown in Table I, which
demonstrates that the amount of the putative serum mineral
complex is not affected by repetitive freezing of the serum
sample.
Centrifugational Evidence for a Complex of Calcium, Phos-
phate, Fetuin, and MGP in the Serum of Etidronate-treated
Rats—We next examined the possible sedimentation of the
serum calcium phosphate complex during centrifugation, a
property that might be anticipated for the complex based on the
fact that calcium phosphate mineral phases typically have
densities about 3-fold greater than serum. As shown in Table
II, centrifugation of serum from rats treated with the 32-mg
dose of etidronate resulted in a pellet containing calcium, phos-
phate, and MGP. When the pellet was dissolved in acid and
analyzed by SDS-PAGE, a major band was found at 59 kDa
that accounted for at least 80% of the Coomassie staining (Fig.
3). When this component was electrophoretically transferred to
polyvinylidene difluoride and subjected to N-terminal protein
sequencing, one sequence was obtained, APQGAGLGFR, which
matches the N-terminal sequence of rat fetuin (21). The other
major band in the gel had an apparent molecular mass of 66
kDa and accounted for about 10% of the total Coomassie stain-
ing; this band was identified as rat serum albumin by N-
terminal sequence analysis. Based on the recovery of fetuin in
the pellet, we estimate the weight ratio of fetuin to mineral
phosphate in the pellet to be 3.4 mg/mg. Western blot analyses,
an example of which is shown in Fig. 3B, revealed that forma-
tion of the protein mineral complex did not significantly in-
crease the total levels of serum fetuin and that formation of the
serum mineral complex consumed about half of the fetuin ini-
tially found in serum.
Because it is conceivable that the nature of the protein min-
eral complex could be affected by the blood coagulation needed
for serum collection, the filtration and centrifugation experi-
ments described above were repeated using heparinized
plasma samples. In the filtration experiment, filtrate and re-
tentate levels of calcium, phosphate, and MGP in plasma from
control rats and from the etidronate-treated rats were each
within 5% of the values reported in Table I. In the centrifuga-
tion experiment, the amount of calcium, phosphate, and MGP
in the supernatant and pellet fractions obtained by centrifug-
ing plasma from control and etidronate-treated rats were each
within 7% of the values reported in Table II, and the SDS gel of
the proteins in the dissolved pellet was indistinguishable from
that shown in Fig. 3. These experiments show that the nature
of the mineral complex does not appear to be affected by the
process of blood coagulation.
In experiments using serum obtained 6 h after administra-
tion of 8 mg of etidronate/100 g, we were unable to demonstrate
the sedimentation of calcium, phosphate, or MGP after 30 min
of centrifugation at 16,000  g. This result indicates that the
putative complex of a calcium phosphate mineral phase and
protein found after the 8 mg/100 g etidronate dose has different
sedimentation properties than the complex found after the 32
mg/100 g dose.
Gel Filtration Evidence for a High Molecular Weight Com-
plex of Calcium, Phosphate, Fetuin, and MGP in the Serum of
Etidronate-treated Rats—To further characterize the calcium
phosphate complex found in the serum of rats treated with the
8 mg/100 g dose of etidronate, we sought to partially purify this
complex by gel filtration over a column of Sephacryl S300 using
10 mM calcium in the buffer to stabilize the putative complex.
As seen in Fig. 4, there is a peak of MGP and phosphate in the
excluded volume position of the chromatogram of serum from
the etidronate-treated rat that is not found in the chromato-
gram of serum from an untreated rat. The MGP antigen recov-
ered in this excluded volume peak accounts for the amount of
MGP antigen in the serum sample applied to the column, and
there was no detectable MGP antigen in the elution position of
the 10-kDa MGP monomer, which is about fraction 40. In
contrast, no BGP antigen could be detected in the high molec-
TABLE II
Effect of centrifugation on serum calcium, phosphate, and
matrix Gla protein
Serum was obtained from 3 40-day-old male rats 6 h after subcutan-
eous injection with etidronate at a dose of 32 mg/100 gm of body weight
and was pooled. A one-ml aliquot of pooled serum was immediately
centrifuged at 16,000  g for 30 min at room temperature. The super-
natant was removed, and the pellet was rinsed once with 1 ml of 0.15 M
NaCl and then dissolved with 1 ml of 50 mM HCl. The data show the
number of mol of calcium, phosphate, and MGP in 1 ml of serum before
centrifugation and in the supernatant and dissolved pellet.
Calcium Phosphate MGP
mol mol ng
Initial serum 9.64 7.49 16,200
Supernatant 6.88 5.84 800
Dissolved pellet 3.27 1.68 14,400
TABLE I
Effect of filtration through a 300-kDa membrane on serum calcium, phosphate, and matrix Gla protein
Serum was obtained from 2 40-day-old male rats 6 h after subcutaneous injection with etidronate at a dose of 8 mg/100 g of body weight and from
2 age-matched control rats. One-ml aliquots of the 4 serum samples were filtered through a 300-kDa molecular mass cut-off membrane using a
Ultrafree CL filtration device, and the levels of calcium, phosphate, MGP, and volume were measured for the filtrate and the retentate fractions
(see “Experimental Procedures” for details). The data show the number of mol of calcium, phosphate, and MGP in 1 ml of serum before filtration
and in the 0.7-ml filtrate and 0.26-ml retentate volumes recovered after filtration. The data are the average of the values for the two control rats
and the two etidronate-treated rats.
Calcium Phosphate MGP
Control Etidronate Control Etidronate Control Etidronate
mol mol ng
Initial serum 2.68 4.30 3.56 5.10 454 14,800
Filtrate 1.20 1.18 2.72 2.98 42 291
Retentate 1.28 2.72 0.98 1.84 284 11,630
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ular mass position in the chromatogram, and all BGP antigen
was recovered in a single peak in the fraction 45 position
expected for the 6-kDa BGP monomer (data not shown). This
result indicates that the association of MGP with the serum
mineral complex is highly specific, since it is well established
that BGP binds strongly to hydroxyapatite in vitro and in
serum (18, 22).
To evaluate the possible presence of other proteins associ-
ated with the serum mineral complex, the Sephacryl S300
fractions corresponding to the high molecular mass phosphate
peak from an etidronate-treated rat (Fig. 4, upper panel) and
the corresponding fractions from a normal rat (Fig. 4, lower
panel) were separately combined with EDTA and fractionated
by SDS-PAGE. As shown in Fig. 5, there is a prominent Coo-
massie-stained protein band in the lanes for the etidronate-
treated animal that is not seen in the lanes for the control
animal, a band with an apparent molecular mass of about 59
kDa. To identify this protein constituent, fraction 23 from the
high molecular mass phosphate peak in the chromatogram of
etidronate-treated rat (Fig. 4, upper panel) was fractionated by
SDS-PAGE followed by electrophoretic transfer to polyvinyli-
dene difluoride. N-terminal protein sequencing of this 59-kDa
band revealed that its sequence matched the N-terminal se-
quence of rat fetuin (21). Comparison of the SDS-PAGE for
fraction 23 from the Sephacryl S300 gel filtration of etidronate
and control rat serum using a more sensitive colloidal Coomas-
sie stain revealed the presence of a band in the 14-kDa position
expected for purified MGP in the lanes from the etidronate-
treated rat but not in the lanes from the control rat (figure not
shown). No other band could be detected in the SDS-PAGE of
fraction 23 from the etidronate-treated rat chromatogram that
was not also found at comparable levels in fraction 23 from the
control rat chromatogram.
To estimate the amount of fetuin in the high molecular mass
FIG. 3. SDS-polyacrylamide gel electrophoresis of the proteins
associated with the serum mineral complex. Panel A, a 7-g ali-
quot of the dissolved pellet from the centrifugation experiment de-
scribed in Table II was dried, dissolved in loading buffer, and then
electrophoresed on a 4–20% polyacrylamide gel and stained with Coo-
massie Brilliant Blue (right lane). Bio-Rad low molecular mass markers
are in the left lane. Panel B, aliquots of the supernatant and dissolved
pellet from a repeat of the experiment described in Table II and aliquots
of serum from the etidronate-treated rat before centrifugation and of
serum from a control rat were electrophoresed on a 4–20% polyacryl-
amide gel. Proteins were transferred to nitrocellulose, incubated with
rabbit antibody against rat fetuin, and detected using alkaline phos-
phatase-conjugated second antibody. Each lane in the gel contains
exactly the same proportion of the original serum sample, and the
intensities of the bands therefore reflect the relative amount of fetuin
antigen in the different fractions examined (see “Experimental
Procedures”).
FIG. 4. Sephacryl S-300 HR filtration of serum from etid-
ronate-treated and control rats. Forty-day-old male rats received a
single subcutaneous dose of 8 mg of etidronate/100 g of body weight or
of vehicle alone, and blood was collected 9 h later. One-ml serum
samples were then immediately applied to a 25-ml column of Sephacryl
S-300 HR equilibrated with 20 mM HEPES, pH 7.4, 0.15 M NaCl, and 10
mM CaCl2. Temperature, 22 °C; fraction size, 0.5 ml. , absorbance at
280 nm; E, g/ml MGP as determined by radioimmunoassay;  g/ml
phosphorus. Upper panel, serum from an etidronate-treated rat; lower
panel, serum from a control rat.
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phosphate peak fractions, we performed two repeat SDS-PAGE
analyses of fractions 22–24 of Fig. 4, upper panel, together with
lanes containing known amounts of pure fetuin. Quantitative
analysis of the amount of Coomassie staining in these fetuin
bands using a densitometer yielded an estimate of 630 g of
fetuin in fractions 22–24. The phosphate content of these frac-
tions is 83 g of phosphate, and the weight ratio of fetuin to
phosphate is 7.6 mg/mg. The total MGP content of fractions
22–24 is 11 g (Fig. 4), and the calculated molar ratio of MGP
to fetuin in these fractions is 1:8.
The rise in serum levels of calcium and phosphate after
etidronate injection is very rapid, with a 21% rise in serum
calcium at 30 min (Fig. 1). To see if this rapid rise in serum
calcium and phosphate is due to the appearance of the fetuin
mineral complex in serum, aliquots of serum obtained 30 min
after the injection of the 8 mg/100 g etidronate dose were also
subjected to gel filtration over the column of Sephacryl S300.
This experiment showed that there is a peak of phosphate in
the excluded volume position of the 30-min serum sample that
is about 25% the amount seen in a 6-h serum sample. SDS gel
electrophoresis further showed that the excluded volume frac-
tions of the 30 min serum sample contained fetuin at a ratio of
fetuin to phosphate of about 7 mg/mg.
Evidence That Etidronate Generates the Serum Mineral
Complex by Inhibiting Bone Mineralization—Previous studies
show that the doses of etidronate used here to cause the ap-
pearance of the complex of calcium, phosphate, fetuin, and
MGP in serum also cause the inhibition of the normal calcifi-
cation of bone and cartilage, resulting in the formation of
unmineralized osteoid in bone and of unmineralized cartilage
in the growth plate (23). When 100-g rats are given a dose of 4
mg of etidronate per day, this inhibition of mineralization is
discontinuous and results in the appearance of alternating
bands of calcification and no calcification in the proximal tibia.
In the present studies we sought to determine whether the
timing of the appearance of the calcium-phosphate-fetuin-MGP
complex in serum correlates with the inhibition of growth plate
cartilage mineralization. As seen in Fig. 6, microradiographs of
the proximal tibial metaphysis of 100-g rats given 4 mg of
etidronate at t  0 and 24 h and killed at 48 h revealed
alternating bands of calcification and no calcification that are
identical to those reported in the earlier study (see Fig. 6 in
Schenk et al. (23)), with inhibition of calcification from 0 to
12 h, calcification from 12 to 24, inhibition of calcification from
24 to 36 h, and calcification from 36 to 48 h. As shown in Fig.
7, the 0–12- and 24–36-h intervals during which calcification
was inhibited are the intervals during which serum levels of
calcium, phosphate, and MGP became elevated, whereas the
12–24- and 36–48-h intervals during which cartilage calcifica-
tion returned to normal are the intervals in which serum levels
of calcium, phosphate, and MGP also returned to normal val-
ues. These results show that the appearance of the serum
mineral complex after etidronate injection correlates with the
timing of the inhibition of growth plate cartilage
mineralization.
Effect of Warfarin Treatment on the Mineral Complex Found
in the Serum of Etidronate-treated Rats—We have previously
shown that the vitamin K antagonist warfarin inhibits the
-carboxylation of MGP and thereby inactivates the calcifica-
tion inhibitory activity of the protein and causes extensive
calcification of arteries and heart valves (5, 6). To determine
whether the -carboxylation of MGP is necessary for the accu-
mulation of the protein in the serum complex of calcium, phos-
phate, and fetuin, rats were injected with warfarin 2 h before
the administration of etidronate to ensure that all MGP syn-
thesized from the time of etidronate administration is non--
carboxylated. Blood samples were then obtained at suitable
times after etidronate injection and analyzed to determine
serum levels of MGP, calcium, and phosphate. As shown in Fig.
8C, warfarin blocked the increase in serum MGP after eti-
dronate administration but did not affect the time course of the
elevation in serum calcium and phosphate (Fig. 8, A and B).
FIG. 5. Electrophoresis of the high molecular mass fractions
from the Sephacryl S300 fractionation of serum from etid-
ronate-treated and control rats. Ten l of fractions 22, 23, and 24
from the chromatograms shown in Fig. 4, upper and lower panels, were
each first mixed with 10 l of 2 loading buffer containing 60 mM EDTA
and then electrophoresed on a 4–20% polyacrylamide gel and stained
with Coomassie Brilliant Blue.
FIG. 6. Effect of two 4-mg/100-g doses of etidronate spaced 24 h
apart on the microradiograph of the proximal tibia. One hundred
gram rats were injected with 4 mg of etidronate at t  0 and 24 h, and
killed at t  48 h. Tibias were removed from the etidronate-treated rats
and from age-matched control rats, fixed in 70% ethanol, embedded in
plastic, cut into 500-m sections, and radiographed. Note the alternat-
ing bands of mineralized and non-mineralized matrix in the microra-
diograph of the proximal tibia from the etidronate-treated rat.
FIG. 7. Effect of two 4-mg/100-g doses of etidronate spaced 24 h
apart on serum levels of phosphate and matrix Gla protein.
Serum was obtained at the indicated times from the rats described in
the legend to Fig. 6, and each serum sample was analyzed to determine
the levels of phosphate and matrix Gla protein. Each data point is the
average of the individually determined levels in six experimental ani-
mals, and the error bars denote the S.D. , serum phosphate, mM; Œ,
serum MGP, g/ml.
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Since warfarin treatment had no effect on serum levels of MGP
in animals that did not receive etidronate, warfarin does not
inhibit the synthesis of MGP per se, only the accumulation of
MGP in serum after etidronate treatment. To further examine
the effects of warfarin on the etidronate response, serum was
obtained at 6 h after etidronate treatment from rats that were
treated concurrently with warfarin. Analysis by Sephacryl
S300 chromatography revealed phosphate levels in the high
molecular mass, excluded volume position that were compara-
ble with phosphate levels in vitamin K-replete, etidronate-
treated rats and MGP levels in the high molecular mass posi-
tion that were only 5% of the level seen in vitamin K-replete,
etidronate-treated rats (chromatogram not shown). These re-
sults demonstrate that the -carboxylation of MGP is critical
for its incorporation into the serum mineral complex and also
show that the MGP that accumulates in this complex must
arise from new MGP synthesis. Because serum calcium and
phosphate levels are not affected by warfarin treatment, the
absence of MGP in the serum mineral complex does not affect
the magnitude of the serum mineral response to etidronate or
the subsequent clearance of the mineral complex from serum.
SDS gel electrophoresis of the high molecular mass phosphate-
containing peak from the Sephacryl S300 chromatogram (data
not shown) demonstrated the presence of fetuin at the level
found in previous experiments (see Fig. 5), which indicates that
the incorporation of fetuin into the serum mineral complex is
independent of the presence of MGP.
DISCUSSION
The present study is the first to report the presence of a
complex of calcium, phosphate, and protein in serum and the
first to isolate this complex and to determine its structure. This
protein mineral complex appears in serum shortly after the
administration of the bisphosphonate etidronate, and within
6 h of injection with a 32 mg/100 g dose of etidronate, the
presence of this complex in serum increases total serum cal-
cium levels by more than 4-fold (to 8.8 mM calcium), phosphate
levels by 2.5-fold (to 8.6 mM phosphate), and MGP levels by
36-fold (to 18 g/ml). Because free calcium and phosphate are
not elevated by etidronate treatment (see Table I), the protein
mineral complex cannot be formed in serum in a physicochem-
ical process driven by the enhanced supersaturation of serum
with respect to calcium phosphate mineral phases. In fact when
enhanced supersaturated conditions are created in serum by a
vitamin D treatment that elevates ionic and total serum cal-
cium by 40%, there is no detectable level of the protein mineral
complex in serum. It is therefore probable that the protein
mineral complex is formed outside of the vascular system as a
consequence of etidronate treatment and subsequently travels
to blood. This model does not rule out the possibility that
changes in the initial mineral complex may occur after its
appearance in serum, and the delayed appearance of MGP in
the complex indeed suggests that the MGP content of the
complex does change after the initial appearance of the com-
plex in blood.
We believe that the serum mineral complex is probably gen-
erated as a consequence of the inhibition of bone mineralization
by etidronate rather than as a consequence of the inhibition of
bone resorption. Several arguments support this hypothesis as
follows. 1) The appearance of the serum mineral complex and
the inhibition of bone mineralization both occur within an hour
after etidronate administration (Fig. 1 and Schenk et al. (23)).
In contrast, the inhibition of bone resorption by etidronate and
other bisphosphonates can only be detected 1–2 days after
injection of the drug (24). 2) There is good agreement between
the timing of the inhibition of bone mineralization and the
appearance of the serum mineral complex after etidronate
treatments spaced 24 h apart (Figs. 6 and 7). 3) The amino
bisphosphonate alendronate does not generate the serum min-
eral complex even though the dose tested here is more than
1000-fold above those needed to inhibit bone resorption in rats
of this age. It has been shown previously that these alen-
dronate doses do not inhibit normal bone mineralization (25).
Although the size of the complex cannot be established from
these studies, the filtration experiments suggest that the com-
plex must be large enough to be retained by a 300-kDa molec-
ular mass cut-off membrane, which supports a size of 300 kDa
or larger, and the gel filtration studies indicate that the com-
plex must be large enough to be in the excluded volume position
of the Sephacryl S300 column, which is consistent with a size of
FIG. 8. Effect of warfarin on serum levels of calcium, phos-
phate, and matrix Gla protein in animals treated with a 8-mg/
100-g dose of etidronate. Eight forty-day-old male Sprague-Dawley
rats were given subcutaneous injections of 8 mg of etidronate per 100 g
at t 0. Four animals also received an injection of 15 mg of warfarin per
100 g 2 h before the etidronate injection. Blood was removed from each
animal at the indicated times and analyzed to determine the levels of
calcium, phosphate, and MGP. Each data point is the average of the
individually determined levels in the four experimental animals in each
treatment group, and the error bars denote the S.D. Panel A, f, serum
calcium, mM, in warfarin-treated rats;, serum calcium, mM, in control
rats. Panel B, , serum phosphate, mM, in warfarin-treated rats; E,
serum phosphate, mM, in control rats. Panel C, Œ, serum MGP, g/ml,
in warfarin-treated rats; ‚, serum MGP, g/ml, in control rats.
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250 kDa or larger. The complex may in fact have a range of
sizes, since half of the complex formed by the 32 mg/100 g
etidronate dose sediments, whereas half of the complex does
not (Table II). The size of the complex may also vary with the
etidronate dose, since the protein mineral complex found in
serum the 8 mg/100 g dose does not sediment upon centrifuga-
tion. Fetuin is the major protein component of the serum min-
eral complex, with an estimated weight ratio of fetuin to min-
eral of 4.4 for the complex found in serum at the 8 mg/100 g
etidronate dose and an estimated ratio of fetuin to mineral of
1.9 at the 32 mg/100 g dose of etidronate. The MGP content of
the serum mineral complex increases with time after eti-
dronate injection, reaching a molar ratio of MGP to fetuin of
1:8. If the average molecular mass of the serum mineral com-
plex were 550,000 daltons, the complex found in serum 6 h
after treatment with the 8 mg/100 g dose of etidronate would
consist of 8 fetuin molecules, 1 MGP molecule, 790 atoms of
calcium, and 580 molecules of phosphate. It should be noted
that these calculations are based on the assumption that the
only protein constituents of the complex are fetuin and MGP
and that the SDS gel shown in Fig. 3 indicates that higher
molecular mass proteins could in fact be present in the com-
plex. Future studies will be needed to identify these compo-
nents and to establish their possible role in the serum complex.
Because free calcium and phosphate levels remain at control
values when serum containing the protein mineral complex is
incubated at room temperature for 24 h, a primary function of
the protein components of the complex may be to inhibit the
growth of the mineral phase component. The protein compo-
nents may also inhibit the aggregation and precipitation of the
mineral phase component, because there is no evidence of the
aggregation and precipitation of a mineral phase after 24 h of
incubation at room temperature. Because the serum complex is
cleared from serum within 6 h of attaining its peak value (Figs.
1 and 7), a secondary function of the protein components may
be to target the complex for clearance from blood.
Role of Fetuin in the Serum Complex—The most abundant
component of the serum complex is fetuin, not mineral or MGP,
and it seems probable that the properties of the complex largely
reflect the presence of fetuin in it. It is our hypothesis that
fetuin molecules aggregate on the surface of the mineral nuclei
and thereby prevent growth of the mineral phase and the
generation of additional crystal nuclei. We believe that the
most likely role for the protein component of fetuin is to medi-
ate the binding of fetuin to mineral and to associate laterally
with other fetuin molecules on the mineral surface to inhibit
crystal growth. We further speculate that the 5 oligosaccharide
moieties of fetuin, which account for 25% of its weight, project
away from the mineral and into the surrounding aqueous
phase. The functions of oligosaccharides in fetuin would be to
lower the density of the mineral complex so that it will not
sediment in serum and to prevent aggregation of one complex
with another.
Previous studies demonstrate that fetuin inhibits the sedi-
mentation of calcium from supersaturated solutions of calcium
and phosphate after centrifugation for 5 min at 15,000 g (26).
Fetuin in fact accounts for roughly half of the inhibitory activ-
ity found in serum. Although the mechanism by which fetuin
inhibits calcium precipitation was not identified in these stud-
ies, the inhibitory activity was shown to be mediated by acidic
amino acids clustered in the D1 cystatin-like domain of fetuin.
Our present results are consistent with the putative calcifica-
tion inhibitor activity of fetuin identified in these earlier stud-
ies and suggest that this action of the protein could be associ-
ated with its ability to form stable, soluble complexes with
mineral nuclei that inhibit nuclei growth and precipitation.
The present studies indicate that most of the fetuin found in
the serum mineral complex originates in the endogenous fetuin
pool found in serum before the injection of etidronate rather
than from the fetuin found in bone. Because the normal con-
centration of fetuin in rats is 1 mg/ml (27) and the amount of
fetuin found in the serum mineral complex is 0.5–0.6 mg/ml,
formation of the complex from the endogenous serum fetuin
pool would be predicted to significantly deplete the serum pool
of monomeric fetuin. Comparison of the amount of fetuin re-
maining in the supernatant and pellet fractions after sedimen-
tation of the complex by centrifugation shows that formation of
the complex at the 32-mg etidronate dose does indeed consume
about half of the fetuin initially present in serum. Direct com-
parison of total fetuin levels present in serum at different times
after a 32-mg etidronate dose also failed to reveal a significant
increase in the serum fetuin pool, as would have been expected
had the fetuin found in the serum mineral complex originated
in bone rather than serum.
Because the mineral component of the serum mineral com-
plex clearly arises from the inhibition of bone mineralization
and fetuin is an abundant constituent of the extracellular bone
matrix, it is possible that some of the fetuin found on the
complex does originate in the bone, perhaps through a direct
effect of etidronate on fetuin synthesis by osteoblasts. This
possibility is supported by the observation that fetuin is syn-
thesized by osteoblasts in fetal rat bone (28, 29) and by fetal rat
osteoblasts in cell culture (28). A number of studies have,
however, failed to find evidence for the synthesis of fetuin or for
the expression of mRNA for fetuin in the bones of adult rats
(19, 29–31). Although these observations indicate that basal
expression of fetuin in the adult rat is undetectable, it remains
possible that fetuin expression by osteoblasts in adult rat bone
could be induced by etidronate treatment and that bone syn-
thesis of the protein could contribute to the formation of the
fetuin mineral complex found in serum after etidronate
injection.
Role of MGP in the Serum Mineral Complex—The present
studies suggest that MGP accumulates in serum after eti-
dronate injection by virtue of its binding to the serum complex.
Because the vitamin K antagonist warfarin completely blocks
the accumulation of MGP in the complex, it is clear that the
MGP that accumulates in the complex arises from new synthe-
sis and that accumulation of MGP in the complex requires the
vitamin K-dependent -carboxylation of the protein. We believe
that the dramatic increase in the total level of serum MGP
after etidronate administration is caused by a reduced rate of
MGP clearance from blood rather than by an increased rate of
MGP synthesis. Serum proteins the size of the 10-kDa MGP
molecule are cleared rapidly by kidney filtration (t1⁄2  5 min),
and the 0.5 g/ml level of MGP found in normal rat serum
consequently reflects a dynamic balance between new synthe-
sis and clearance, with 0.25 g/ml/5 min of new MGP synthesis
compensating for the amount of MGP lost by kidney filtration.
MGP bound to the much larger serum mineral complex would
evade this clearance mechanism and, therefore, accumulate in
serum. This hypothesis accounts for the approximately linear
accumulation of MGP in serum during the first 6 h after eti-
dronate injection (Fig. 1) as well as the total increase in serum
MGP found at 6 h.2 The alternative hypothesis for the 30-fold
increase in serum MGP after etidronate administration is that
the presence of the fetuin mineral complex in serum could
2 In 6 h the amount of MGP that could accumulate in serum by
evading kidney clearance would be the rate of appearance of newly
synthesized MGP in serum, 0.25 g/ml/5 min, 360 min, which is 18
g/ml. This number is in good agreement with the actual level of the
protein in serum at this time (Fig. 2).
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stimulate a dramatic increase in the rate of MGP synthesis by
tissues that contribute MGP to blood. Although we cannot rule
out this hypothesis entirely, investigations of the level of MGP
mRNA in several tissues have failed to reveal a significant
increase at 6 h after etidronate treatment.
The present studies demonstrate that MGP binds to the
fetuin mineral complex with considerable strength and speci-
ficity. The gel filtration analysis of the elution position of MGP
antigen (Fig. 4, upper panel) failed to detect the presence of any
MGP in the elution position of the MGP monomer, which indi-
cates that the concentration of monomeric serum MGP in equi-
librium with MGP bound to the complex must be very low. The
binding of MGP to the fetuin mineral complex must also be
highly specific, since we could detect no other Coomassie-
stained proteins associated with the complex other than fetuin
and MGP (see Fig. 5). The specificity of this interaction is
further supported by the observation that the structurally re-
lated vitamin K-dependent protein, BGP, fails to accumulate in
the complex despite its known high affinity for hydroxyapatite
(22).
The ability of MGP to bind with great avidity to the mineral
complex despite the presence of fetuin suggests that MGP could
in fact have a greater affinity for mineral than fetuin and so
could be the stronger inhibitor of crystal growth. This possibil-
ity is supported by the observation that targeted deletion of the
MGP gene in the mouse causes rapid and extensive calcifica-
tion of the elastic lamellae of arteries beginning at birth (4),
whereas fetuin-deficient mice have no evidence of soft tissue
calcification except for the specialized case of occasional micro-
calcifications in a few muscles of some female retired breeder
mice (32). We speculate that the failure of soft tissues to calcify
in the fetuin-deficient mouse could be due in part to the ability
of MGP to inhibit calcification and that the capacity of serum
MGP to inhibit calcification is adequate to prevent soft tissue
calcification under normal physiological circumstances. One
prediction of this hypothesis is that a high capacity stress on
the ability to inhibit calcification in serum, such as is imposed
by a high dose of etidronate, will cause fetuin-deficient mice to
experience a massive rate of mineral formation, a mineraliza-
tion that cannot be retarded by the low capacity inhibitory
function of serum MGP. A second prediction of this hypothesis
is that warfarin treatment and the fetuin gene deletion should
act synergistically to produce more rapid ectopic calcification
than is found with either condition alone.
Although we have focused here on the ability of fetuin and
MGP to prevent the growth of the mineral component of the
serum complex, it is important to note that both proteins have
other important biological activities. Fetuin binds transform-
ing growth factor- and bone morphogenic protein-2 (BMP-2)
and blocks the osteogenic activity of these cytokines in cell
culture assays (33, 34). MGP also binds BMP-2 and blocks the
activity of BMP-2 on cells in culture (35). An important goal of
future studies will be to determine whether fetuin and MGP
retain their ability to block the activity of cytokines when they
are part of the serum complex.
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